Ohcanbohtosat - David M. Pariser
- Čájehuvvo 1 - 20 / 33
- Sirdás čuovvovaš siidui
-
1
Topical 0.5% Ivermectin Lotion for Treatment of Head Lice Dahkki David M. Pariser, Terri L. Meinking, Margie Bell, William G. Ryan
Almmustuhtton 2012Artigo -
2
The Epidemiology, Etiology, and Pathophysiology of Onychomycosis Dahkki Richard K. Scher, Phoebe Rich, Boni E. Elewski, David M. Pariser
Almmustuhtton 2013Revisão -
3
-
4
-
5
Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States Dahkki Alexa B. Kimball, Jennifer Schenfeld, Neil A. Accortt, Mary S. Anthony, Kenneth J. Rothman, David M. Pariser
Almmustuhtton 2015Artigo -
6
-
7
Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety... Dahkki Robert Bissonnette, David M. Pariser, Norman Wasel, Joana Gonçalves, Robert M. Day, Rongdean Chen, Michael Sebastian
Almmustuhtton 2016Artigo -
8
Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follo... Dahkki Eduardo Tschen, David S.Y. Wong, David M. Pariser, F E DUNLAP, Anna Houlihan, Mary Beth Ferdon
Almmustuhtton 2006Artigo -
9
A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patient... Dahkki Kim Papp, David M. Pariser, Mary Catlin, G. Wierz, Greg Ball, B. Akinlade, Bernhardt Zeiher, James G. Krueger
Almmustuhtton 2015Artigo -
10
Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis Dahkki Amy S. Paller, Elaine C. Siegfried, David M. Pariser, Kara Rice, Mona Trivedi, Jan Iles, David H. Collier, Greg Kricorian, Richard Langley
Almmustuhtton 2016Artigo -
11
Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials Dahkki Linda Stein Gold, Mark Lebwohl, Jeremy Sugarman, David M. Pariser, Tina Lin, Gina Martin, Radhakrishnan Pillai, Robert J. Israel, Tage Ramakrishna
Almmustuhtton 2018Artigo -
12
Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials Dahkki Dee Anna Glaser, Adelaide A. Hebert, Alexander Nast, William Philip Werschler, Lawrence Green, Richard D. Mamelok, Janice Drew, John Quiring, David M. Pariser
Almmustuhtton 2018Artigo -
13
TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial Dahkki Seth Forman, David M. Pariser, Yves Poulin, Michael S. Vincent, Steven A. Gilbert, Elizabeth Kieras, Ruolun Qiu, Dahong Yu, Jocelyne Papacharalambous, Christopher Tehlirian, Elena Peeva
Almmustuhtton 2020Artigo -
14
Etanercept Treatment for Children and Adolescents with Plaque Psoriasis Dahkki Amy S. Paller, Elaine C. Siegfried, Richard Langley, Alice B. Gottlieb, David M. Pariser, Ian Landells, Adelaide A. Hebert, Lawrence F. Eichenfield, Vaishali Patel, Kara Creamer, Angelika Jahreis
Almmustuhtton 2008Artigo -
15
Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies Dahkki Mark Boguniewicz, Andrew Alexis, Lisa A. Beck, Julie Block, Lawrence F. Eichenfield, Luz Fonacier, Emma Guttman‐Yassky, Amy S. Paller, David M. Pariser, Jonathan I. Silverberg, Mark Lebwohl
Almmustuhtton 2017Revisão -
16
Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis Dahkki Eric L. Simpson, Laurent Eckert, Abhijit Gadkari, Usha G. Mallya, Min Yang, Lauren Nelson, T. Michelle Brown, Matt Reaney, Puneet Mahajan, Isabelle Guillemin, Mark Boguniewicz, David M. Pariser
Almmustuhtton 2019Artigo -
17
A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis Dahkki Mark Lebwohl, Stephen K. Tyring, Tiffani K. Hamilton, Darryl Toth, Scott D. Glazer, Naji Tawfik, Patricia A. Walicke, Wolfgang Dummer, Xiaolin Wang, Marvin R. Garovoy, David M. Pariser
Almmustuhtton 2003Artigo -
18
Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT) Dahkki David M. Pariser, Eric L. Simpson, Abhijit Gadkari, Thomas Bieber, David J. Margolis, T. Michelle Brown, Lauren Nelson, Puneet Mahajan, Matthew Reaney, Isabelle Guillemin, Usha G. Mallya, Laurent Eckert
Almmustuhtton 2019Artigo -
19
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the op... Dahkki Diamant Thaçi, Ronald Vender, Menno A. de Rie, Curdin Conrad, David M. Pariser, Bruce Strober, Veerle Vanvoorden, Maggie Haitian Wang, Cynthia Madden, Dirk De Cuyper, Alexa B. Kimball
Almmustuhtton 2023Artigo -
20
OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results Dahkki Alexa B. Kimball, Kenneth J. Rothman, Gregory Kricorian, David M. Pariser, Paul S. Yamauchi, Alan Menter, Craig Teller, Girish Aras, Neil A. Accortt, Michele Hooper, Kara Rice, Joel M. Gelfand
Almmustuhtton 2014Artigo
Ohcanreaiddut:
Laktáseaddji fáttát
Medicine
Dermatology
Internal medicine
Psoriasis
Randomized controlled trial
Adverse effect
Pathology
Surgery
Alternative medicine
Clinical endpoint
Placebo
Clinical trial
Pharmacology
Plaque psoriasis
Atopic dermatitis
Disease
Etanercept
Psoriasis Area and Severity Index
Computer science
Discontinuation
Gastroenterology
Intensive care medicine
Nursing
Quality of life (healthcare)
Adalimumab
Biology
Body surface area
Cancer
Chemistry
Confidence interval